Monday, November 28, 2011

Report: Cancer drug developer Onyx looking at sale, other options

Onyx Pharmaceuticals Inc. is looking at options, including a possible sale, as it awaits an FDA decision on its multiple myeloma treatment carfilzomib, according to Bloomberg.
The stock price of the South San Francisco company (NASDAQ: ONXX) was up $5.62, or nearly 15 percent, to $43.46 in late-afternoon trading.

No comments:

Post a Comment